Fröhlich S, Murphy N, Ryan D, Boylan J F
Department of Anaesthesia and Intensive Care Medicine, St Vincent's University Hospital, Dublin, Ireland.
Anaesth Intensive Care. 2013 Jul;41(4):463-72. doi: 10.1177/0310057X1304100405.
Acute respiratory distress syndrome is one of the leading causes of death in critically ill patients. Recent advances in supportive care have led to a moderate improvement in mortality. In particular, a much lower mortality rate than expected was evident in the severest category of patients (requiring extracorporeal membrane oxygenation) in Australia during the recent H1N1 pandemic. Though improvements in supportive care may have provided some benefit, there remains an absence of effective biological agents that are necessary to achieve further incremental reduction in mortality. This article will review the evidence available for current treatment strategies and discuss future research directions that may eventually improve outcomes in this important global disease.
急性呼吸窘迫综合征是危重症患者死亡的主要原因之一。支持性治疗的最新进展已使死亡率有适度改善。特别是,在最近甲型H1N1流感大流行期间,澳大利亚最严重类别的患者(需要体外膜肺氧合)的死亡率明显低于预期。尽管支持性治疗的改善可能带来了一些益处,但仍缺乏有效的生物制剂,而这对于进一步逐步降低死亡率是必要的。本文将综述当前治疗策略的现有证据,并讨论未来的研究方向,这些研究方向最终可能改善这种重要的全球性疾病的治疗效果。